Hemoglobin (Hb) is the main carrier of oxygen in human body and its amount will affect the oxygen content in body and tumor. Decreased Hb level will cause a decline of blood oxygen leading to tumor hypoxia and increased hypoxic cells, which will affect the efficacy of radiotherapy [1] . Rades .
[2] and Schafer . [3] have found that anemia is an independent prognostic factor affecting the local control rate and survival rate in patients with head and neck squamous cell carcinoma, and emphasized that the patients with anemia should be paid attention to. The same result also appears in the studies of cervical and endometrial cancer [ 4 , 5 ] . However , is the Hb level before treatment [ 6 ] , during treatment [7] or after treatment [8] affecting the prognosis in the end? Individual reports are not consistent. The reports about the impact of Hb level on the prognosis of patients with nasopharyngeal carcinoma (NPC) are limited. Chua . [9] studied 334 NPC patients receiving sequential radiotherapy and chemotherapy or radiotherapy alone, and found that the Hb level during radiotherapy was an important prognostic factor affecting the local control rate and survival rate, but the Hb level before radiotherapy did not. However, this study only analyzed the static Hb level before and during treatment, and did not take into account the effect of dynamic changes of Hb level during treatment on the prognosis. Rutkowski . [10] found that the local control rate of laryngeal cancer patients with decreased Hb level during radiotherapy was significantly lower than that of those without. Therefore, we hypothesized the continuous decline of Hb level during radiotherapy might affect the prognosis of NPC patients. In this study, we analyzed the clinical data of 520 NPC 窑Original Article窑 patients treated in our hospital to explore the effect of Hb level before, during, and after treatment and its dynamic changes on the prognosis.
A total of 600 patients were randomly selected on the computer using SAS software from 2100 NPC patients treated at Sun Yatsen University Cancer Center between January 1, 2000 and December 31, 2002. The patients meeting the following criteria were enrolled: (1) pathologically proved NPC; (2) at first treatment; (3) receiving radical radiotherapy. A total of 520 patients met the above criteria, including 416 men and 104 women, with a mantowoman ratio of 4 ∶ 1. The median age was 46 years old (range, 18 to 78 years). Of the 520 patients, 518 had poorly differentiated squamous cell carcinoma and 2 had adenoid cystic carcinoma. Hb level was measured before radiotherapy, ranging from 76 to 211 g/L, with a mean value of 143 g/L and a median value of 144 g/L. The Hb level during radiotherapy took the average of Hb values weekly during radiotherapy, ranging from 65 to 181 g/L, with a mean value of 131 g/L and a median value of 132 g/L. Hb level after radiotherapy was defined as the Hb value at the last week of radiotherapy, ranging from 64 to 178g/L, and the mean and median values were both 129 g/L. The patients were stratified into anemia and normal Hb level groups by the Hb level before, during and after radiotherapy according to the anemia standard of World Health Organization (Hb level < 130 g/L in men and < 120 g/L in women). According to the dynamic Hb changes before, during and after radiotherapy, 293 (56.3% ) patients were classified as Hb continuous decrease group (before radiotherapy > during radiotherapy > after radiotherapy) and 227 (43.7%) as nondecreased group.
Radiotherapy: Most patients received conventional fractionation radiotherapy with high energy 68 MV Xray by linear accelerator. Isocenter radiation by faceneck joint field with low melting point lead block was used, and the radiation field included the skull base, nasopharynx and neck. Faceneck joint field and lower cervical anterior tangent field were irradiated firstly, with anterior nasal field added in some patients, to a total dose of 36 Gy, and then followed by bilateral preauricular fields plus anterior tangent field to a total dose of 60 to 78 Gy.
Chemotherapy: A total of 219 patients received combined radiochemotherapy, including 209 received induction chemotherapy (mostly was cisplatin (DDP) plus 5fluorouracil (5FU)) for 1 to 2 cycles and 10 received concurrent chemotherapy with DDP or 5FU alone for 1 to 3 cycles.
The patients were followed up by reexamination, telephone, letter, and so on. Survival time was calculated from the start of treatment. The 1, 3 and 5year followup rates were 97.1% , 95.6% and 94.2%. SPSS13.0 software was used for statistical analysis. Life table method was used to calculate survival rates, the KaplanMeier method was used for survival analysis, a logrank test was used for the comparison between the groups, and the Cox regression model was used for multivariate prognostic analysis. A value less than 0.05 was considered statistically significant.
The 1, 3 and 5year local recurrencefree survival (LRFS) rates were 82.8% , 66.2% and 59.9% , and the overall survival (OS) rates were 87.8%, 75.2% and 66.2% for all patients.
Before radiotherapy, the 5year LRFS rates were 60.9% in anemia group and 63.9% in normal Hb level group ( = 0.337), and the 5year OS rates were 65.2% and 71.0% ( = 0.299). During radiotherapy, the 5year LRFS rates were 56.7% in 
Figure1 Local recurrence鄄 free survival (LRFS) curves of nasopharyngeal cancer (NPC) patients with different levels of hemoglobin (Hb) during radiotherapy
The 5鄄 year LRFS rate is significantly lower in the patients with anemia during radiotherapy than in those without anemia. anemia group and 67.9% in normal Hb level group ( = 0.013) ( Table 2 , Figure 1) , and the 5year OS rates were 61.0% and 75.9% ( = 0.001) (Figure 2 ). After radiotherapy, the 5year LRFS rates were 59.6% in anemia group and 64.9% in normal Hb level group ( = 0.169), and the 5year OS rates were 65.0% and 71.9% ( = 0.090).
Further stratified analysis found that for T12N03 patients, the OS rate was significantly lower in anemia group during radiotherapy than in normal Hb level group ( = 0.001) ( Figure  3 ), while for T12N01 (clinical stages I and II) and T34N03 patients, no significant differences were observed between the two groups ( = 0.590, = 0.500).
The 5year LRFS rates were 59.1% in Hb continuous decrease group and 69.3% in nondecrease group ( = 0.032), and the 5year OS rates were 66.2% and 76.4% ( = 0.011), respectively (Figures 4 and 5) .
Further stratified analysis found that for the patients without anemia before radiotherapy, the LRFS and OS rates were significantly lower in Hb continuous decrease group than in in nondecrease group ( = 0.012, = 0.005); while for those with anemia before radiotherapy, no significant differences were observed between the two groups ( = 0.920, = 0.530). 
Figure 4 LRFS curves of patients with different Hb dynamic change trends
The 5鄄 year LRFS rate is significantly lower in the patients in Hb decreased group than in those in Hb non鄄 decreased group. 
Figure 5 OS curves of patients with different Hb dynamic change trends
The 5鄄 year OS rate is significantly lower in the patients in Hb decreased group than in those in Hb non鄄 decreased group.
Figure 6 LRFS curves of patients at different T stages
The 5鄄 year LRFS rate is significantly lower in the patients at stages T3-4 than in those at stages T1-2.
The patients with continuously decreased Hb were stratified into two groups according to the Hb level before treatment. No significant differences in LRFS rates ( = 0.871) and OS rates ( = 0.574) were observed between the patients with and those without anemia before radiotherapy.
Univariate analysis showed that age and T stage were prognostic factors affecting the LRFS rate. The patients younger than 46 years had a higher LRFS rate than those no less than 46 years old, and T12 patients had a significantly higher LRFS rate than T34 patients (Table 2, Figure 6 ).
Multivariate analysis revealed that T stage, age and the Hb level during radiotherapy were potential independent prognostic factors affecting the LRFS rate (Table 3); T stage, age, N stage and Hb dynamic change were potential independent prognostic factors affecting the OS rate (Table 4) .
In this article, we studied the impacts of Hb level on the prognosis of NPC patients, and found that only the Hb level during radiotherapy was a prognostic factor affecting the LRFS and OS rates. The patients with anemia during treatment had significantly lower LRFS rate and OS rate than those without. Multivariate analysis showed that anemia during radiotherapy might be an independent prognostic factor affecting the LRFS rate. Our results are similar with that Chua .
[9] reported. We also found that age and T stage might be independent prognostic factors affecting the LRFS rate, and that the patients with continuously decreased Hb during radiotherapy had lower LRFS rate and OS rate.
Nordsmark . [11] thought that Hb was an important prognostic factor affecting the LRFS rate in head and neck cancer patients treated by radiotherapy. Similarly, we also found that the patients with anemia during radiotherapy had a lower LRFS rate. The reason may be anemia promotes tumor angiogenesis and causes tumor cells resisting apoptosis signal [12, 13] , and thus affects the efficacy of cancer treatment. In addition, anemia leads to an increase of hypoxic cells, which are resistant to radiotherapy and are considered as a main reason of local uncontrolled disease or recurrence after radiotherapy. Evans . [14] found that hypoxic cells exist in almost all solid tumors, generally account for 10% to 20% of all tumor cells, some as high as 50% . Most of hypoxic cells are in the G 0 phase of cell cycle, tend to have no or slow proliferation and be insensitive to radiotherapy and chemotherapy, and become one of the reasons why cancer is difficult to cure and easy to relapse. It may also be one of the reasons why NPC patients have a rising survival rate but the local recurrence rate is still as high as 20% to 40% [15] . Significantly, we found that for patients with stageI and II diseases, anemia during radiotherapy had no significant effect on their survival rate; while for patients at stage T12, anemia affected the survival rate obviously. This may be because patients with stageI and II diseases have relatively early N stages, N0 or N1, while some of patients at stage T12 have late N stages, N2 or N3. The latter patients have relatively poor performance status, as well as easily suffer from anemia because of tumor infiltration, so the prognosis is relatively poor and the survival rate decreases.
During treatment, Hb level will decrease due to the myelosuppression caused by radiotherapy and chemotherapy, tumor infiltration, as well as loss of appetite and nutritional deficiency caused by the reactions of chemotherapy and radiotherapy. The reason for the poor efficacy in patients with continuously decreased Hb is considered that the continuously decreased Hb during radiotherapy leads to reduced level of blood oxygen and causes tissue hypoxia, which increases hypoxic tumor cells and thus affects the efficacy of radiotherapy [1] . Rudat . [16] found that hypoxic tumor cell was an unfavorable factor affecting the local control rate and survival rate in head and neck cancer patients treated by radiotherapy. Tumor cells in hypoxic condition will highly express hypoxiainducible factor1 (HIF1) which plays regulatory roles through binding to hypoxiaresponsive elements that regulate downstream target genes (VEGF, p53, EPO, and so on). For example, HIF1 induces cell cycle arrest by inhibiting protooncogene , and leads to the enhancement of malignant behavior of tumor cells [17] , which become radiation resistant and thus affect the therapeutic effect.
Multivariate analysis found that continuously decreased Hb during radiotherapy might be an independent prognostic factor affecting the OS rate, suggesting that we should observe the changes of Hb during radiotherapy. Active treatments should be used for patients with continuously decreased Hb to treat anemia and prevent the decline of Hb. Common clinical treatments of anemia include blood transfusion, erythropoietin, and so on. However, it has been reported [18] that blood transfusion might cause immune suppression and increase the risk of infection from blood transfusion, and the shortage of blood also restricts the application. Therefore, erythropoietin is more and more used in clinic. Glaser .
[19] studied 191 patients with oral cancer and oropharyngeal cance r, and found that erythropoietin could significantly improve the LRFS and OS rates. Similarly, Rades .
[20] used erythropoietin in 42 patients with esophageal cancer, as compared with the control group, the 2year OS rates were 32% and 8% ( = 0.009) and 2year LRFS rates were 67% and 15% ( = 0.001), both of which were significantly improved. Charu .
[21] also found that erythropoietin could increase Hb level, reduce blood transfusion and significantly improve patients爷 quality of life. Nevertheless, Smith . [22] thought that erythropoietin cannot prolong the survival time and benefit patients. Therefore, for the patients with low Hb level during radiotherapy, the specific treatment for anemia needs further clinical study.
